Please assess the completion status of the following clinical trial:

Trial Title: Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pathologically confirmed malignancy for which treatment with a fluoropyrimidine is considered to be in the patient's best interest~2. Age ≥ 18 years~3. Able and willing to give written informed consent~4. WHO performance status of 0, 1 or 2~5. Life expectancy of at least 12 weeks~6. Able to swallow and retain oral medication~7. Able and willing to undergo blood sampling for pharmacogenetic and phenotyping analysis~8. Minimal acceptable safety laboratory values (ANC, platelet count, hepatic function, renal function)~Additional inclusion criteria for patients in subgroup of study:~1. Able and willing to undergo blood sampling and breath sampling at several time points~2. Able and willing to receive uracil for the test dose assay~3. Able and willing to receive \[2-13C\] -labeled uracil for the breath test~Exclusion Criteria:~1. Prior treatment with fluoropyrimidines~2. Patients with known substance abuse, psychotic disorders, and/or other diseases expected to interfere with study or the patient's safety~3. Women who are pregnant or breast feeding~4. Both men and women who refuse to use reliable contraceptive methods throughout the study (adequate contraceptive methods are: condom, sterilization, other barrier contraceptive measures preferably in combination with condoms)~5. Patients with a homozygous polymorphic genotype or compound heterozygous genotype for DPYD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- heterozygous carrier of DPYD variant (Type: EXPERIMENTAL): Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD\*2A, c.2846A\>T, c.1236G\>A/HapB3 and DPYD\*13) that are found to be heterozygous for one of these SNPs
- wild type for DPYD (Type: EXPERIMENTAL): Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD\*2A, c.2846A\>T, c.1236G\>A/HapB3 and DPYD\*13) that are found to be wild type for these SNPs

Based on this trial design, predict the completion outcome and termination type (if applicable).